Floatz logo

Niraparib

Oligometastatic Disease

MedSIRSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Oligometastatic Disease cohort.

Asset / SponsorPhaseRating
Eovist
University of Colorado, Denver
Phase 4B
GADOBENATE DIMEGLUMINE
University of Colorado, Denver
Phase 4B
FLUOROURACILUM
UMC Utrecht
Phase 2CCC
Eloxatin
University of Cologne
Phase 2CCC
PREDNISONE TABLETS
University of Michigan Rogel Cancer Center
Phase 2CCC

View all 20 →

Same molecule, other indications

Niraparib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative ·
66 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →